“Hepatitis D - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Hepatitis D pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Hepatitis D Understanding
Hepatitis D : Overview Hepatitis D, also known as “delta hepatitis,” is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as “coinfection”) or get hepatitis D after first being infected with the hepatitis B virus (known as “superinfection”). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection.
"Hepatitis D - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis D pipeline landscape is provided which includes the disease overview and Hepatitis D treatment guidelines. The assessment part of the report embraces, in depth Hepatitis D commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis D collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis D R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis D.
Hepatitis D Emerging Drugs Chapters This segment of the Hepatitis D report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatitis D Emerging Drugs • Lonafarnib: Eiger Biopharmaceuticals
Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly. Lonafarnib has been dosed in over 120 HDV-infected patients across international academic centers and is in Phase 3 development for HDV with a single, pivotal trial. Lonafarnib has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Fast Track and now Breakthrough designation by U.S. FDA. Lonafarnib is not approved for any indication, and is licensed from Merck Sharp & Dohme Corp. (known as MSD outside of the United States and Canada).
• JNJ 73763989: Arrowhead Pharmaceuticals
JNJ 73763989 (formerly ARO HBV) is an RNA interference (RNAi) therapeutic, being developed by Arrowhead Pharmaceuticals for the treatment of patients with hepatitis B and hepatitis D infections.
Further product details are provided in the report……..
Hepatitis D: Therapeutic Assessment This segment of the report provides insights about the different Hepatitis D drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Hepatitis D
There are approx. 4+ key companies which are developing the therapies for Hepatitis D. The companies which have their Hepatitis D drug candidates in the most advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.
This report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hepatitis D: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis D therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis D drugs.
Hepatitis D Report Insights • Hepatitis D Pipeline Analysis
• Therapeutic Assessment • Unmet Needs
• Impact of Drugs
Hepatitis D Report Assessment • Pipeline Product Profiles
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Hepatitis D drugs?
• How many Hepatitis D drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis D?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis D therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis D and their status?
• What are the key designations that have been granted to the emerging drugs?
200 pages •
By The Business Research Company
• Mar 2021
Major players in the ultra-low temperature freezers market are Arctiko, Eppendorf, Esco Micro Pte Ltd, Haier, Helmer Scientific, Bionics Scientific Technologies (P). Ltd, PHC Holdings Corporation, Labcold Ltd, Remi Group, and Stirling Ultracold. The global ultra-low temperature freezers market is expected to decline from $633.94 million...
Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They also provide required nutrients to the patients suffering from diabetes, cancer and other diseases. Intravenous solutions...
573 pages •
By Global Industry Analysts
• Apr 2021
- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the...
278 pages •
By Global Industry Analysts
• Apr 2021
- Global Anatomic Pathology Market to Reach $26.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anatomic Pathology estimated at US$18.7 Billion in the year 2020, is projected to reach a revised size of US$26.3 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027....
185 pages •
By Global Industry Analysts
• Apr 2021
- Global Pathology Instruments Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pathology Instruments estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027....
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Pathology Instruments Market 2021-2025 The analyst has been monitoring the pathology instruments market and it is poised to grow by $ 1.23 bn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on pathology instruments market provides a holistic analysis, market size and forecast,...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.